Silgard

RSS
Withdrawn

This medicine's authorisation has been withdrawn

human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)
MedicineHumanWithdrawn
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 18 February 2019, the European Commission withdrew the marketing authorisation for Silgard (human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Merck Sharp & Dohme Limited, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Silgard was granted marketing authorisation in the EU on 19 September 2006 for prevention of diseases caused by specific human papillomavirus (HPV) types: cervical and anal cancer, precancerous or dysplastic lesions in the anus and female genitals, and genital warts. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2011. 

Silgard was a duplicate application to Gardasil, which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for Gardasil and Gardasil 9.

The European Public Assessment Report (EPAR) for Silgard is updated to reflect that the marketing authorisation is no longer valid.

български (BG) (701.82 KB - PDF)

View

español (ES) (579 KB - PDF)

View

čeština (CS) (636.1 KB - PDF)

View

dansk (DA) (554.76 KB - PDF)

View

Deutsch (DE) (557.67 KB - PDF)

View

eesti keel (ET) (550.61 KB - PDF)

View

ελληνικά (EL) (691.22 KB - PDF)

View

français (FR) (581.12 KB - PDF)

View

hrvatski (HR) (605.32 KB - PDF)

View

italiano (IT) (554.77 KB - PDF)

View

latviešu valoda (LV) (661.09 KB - PDF)

View

lietuvių kalba (LT) (608.16 KB - PDF)

View

magyar (HU) (655.15 KB - PDF)

View

Malti (MT) (664.08 KB - PDF)

View

Nederlands (NL) (580.36 KB - PDF)

View

polski (PL) (634.02 KB - PDF)

View

português (PT) (578.72 KB - PDF)

View

română (RO) (584.8 KB - PDF)

View

slovenčina (SK) (664.82 KB - PDF)

View

slovenščina (SL) (652.39 KB - PDF)

View

Suomi (FI) (590.72 KB - PDF)

View

svenska (SV) (554.75 KB - PDF)

View

Product information

български (BG) (2.57 MB - PDF)

View

español (ES) (1.55 MB - PDF)

View

čeština (CS) (2.22 MB - PDF)

View

dansk (DA) (1.45 MB - PDF)

View

Deutsch (DE) (1.59 MB - PDF)

View

eesti keel (ET) (1.44 MB - PDF)

View

ελληνικά (EL) (2.71 MB - PDF)

View

français (FR) (1.54 MB - PDF)

View

hrvatski (HR) (1.56 MB - PDF)

View

íslenska (IS) (1.47 MB - PDF)

View

italiano (IT) (1.6 MB - PDF)

View

latviešu valoda (LV) (2.23 MB - PDF)

View

lietuvių kalba (LT) (1.5 MB - PDF)

View

magyar (HU) (2.2 MB - PDF)

View

Malti (MT) (2.32 MB - PDF)

View

Nederlands (NL) (1.61 MB - PDF)

View

norsk (NO) (1.44 MB - PDF)

View

polski (PL) (2.28 MB - PDF)

View

português (PT) (1.56 MB - PDF)

View

română (RO) (1.58 MB - PDF)

View

slovenčina (SK) (2.2 MB - PDF)

View

slovenščina (SL) (2.13 MB - PDF)

View

Suomi (FI) (1.49 MB - PDF)

View

svenska (SV) (1.49 MB - PDF)

View
Latest procedure affecting product information: WS/1349/G
18/02/2019
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (570.4 KB - PDF)

View

español (ES) (490.26 KB - PDF)

View

čeština (CS) (550.1 KB - PDF)

View

dansk (DA) (488.88 KB - PDF)

View

Deutsch (DE) (481.35 KB - PDF)

View

eesti keel (ET) (487.32 KB - PDF)

View

ελληνικά (EL) (609.95 KB - PDF)

View

français (FR) (488.1 KB - PDF)

View

italiano (IT) (485.69 KB - PDF)

View

latviešu valoda (LV) (535.39 KB - PDF)

View

lietuvių kalba (LT) (527.3 KB - PDF)

View

magyar (HU) (546.57 KB - PDF)

View

Malti (MT) (555.36 KB - PDF)

View

Nederlands (NL) (492.97 KB - PDF)

View

polski (PL) (534.97 KB - PDF)

View

português (PT) (484.98 KB - PDF)

View

română (RO) (522.22 KB - PDF)

View

slovenčina (SK) (534.56 KB - PDF)

View

slovenščina (SL) (553.01 KB - PDF)

View

Suomi (FI) (491.71 KB - PDF)

View

svenska (SV) (491.13 KB - PDF)

View

Product details

Name of medicine
Silgard
Active substance
  • human papillomavirus type 6 L1 protein
  • human papillomavirus type 11 L1 protein
  • human papillomavirus type 16 L1 protein
  • human papillomavirus type 18 L1 protein
International non-proprietary name (INN) or common name
human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)
Therapeutic area (MeSH)
  • Papillomavirus Infections
  • Uterine Cervical Dysplasia
  • Condylomata Acuminata
  • Immunization
Anatomical therapeutic chemical (ATC) code
J07BM01

Pharmacotherapeutic group

Vaccines

Therapeutic indication

Silgard is a vaccine for use from the age of 9 years for the prevention of:

  • premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types;
  • genital warts (condyloma acuminata) causally related to specific HPV types.

See sections 4.4 and 5.1 for important information on the data that support this indication.

The use of Silgard should be in accordance with official recommendations.

Authorisation details

EMA product number
EMEA/H/C/000732
Marketing authorisation holder
Merck Sharp Dohme Ltd

Hertford Road
Hoddesdon
Hertfordshire
EN11 9BU
United Kingdom

Marketing authorisation issued
19/09/2006
Withdrawal of marketing authorisation
18/02/2019
Revision
33

Assessment history

This page was last updated on

Share this page